11.08.20at, Bioengineered Skin Substitutes

By 09/30/2026: Billing team must update billing software to reflect coverage changes for bioengineered skin substitutes per policy 11.08.20at. CRITICAL: Reclassify HCPCS codes A2046, A2047, A2048, A2049, A2050, Q4207, Q4223, and Q4243 as always experimental/investigational (will be denied for coverage). Update G-codes G0681, G0682, G0683, G0684 effective date to 01/01/2026. Revise codes A2040, A2041, A2042, A2043, A2045, Q4298, Q4299 per revised policy criteria. Before submitting claims on or after 10/01/2026: Providers must verify requested bioengineered skin substitute is on the approved list for the specific wound indication (diabetic foot ulcer, venous leg ulcer, epidermolysis bullosa, or second/third-degree burn). Document that wound meets ALL medically necessary criteria including: skin deficit ≥1.0 cm², clean granular base without tendon/muscle/bone exposure, adequate circulation (ABI ≥0.60), appropriate failed conservative care period (4 weeks for most wounds, 30 days for VLU), and compliance with documented wound care measures. Add documentation requirements to encounter forms and EMR templates. Claims submitted without this documentation or for non-approved products will be denied. Educate clinical staff that bioengineered skin substitutes for acute wounds, post-Mohs procedures, and post-surgical use are experimental/investigational and not covered.